Glenmark Life Sciences Limited (IN:ALIVUS)
:ALIVUS
Want to see IN:ALIVUS full AI Analyst Report?
Total Valuation
Glenmark Life Sciences Limited has a market cap or net worth of ₹127.34B. The enterprise value is ₹124.35B.
Market Cap₹127.34B
Enterprise Value₹124.35B
Share Statistics
Glenmark Life Sciences Limited has 122,736,350 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding122,736,350
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Glenmark Life Sciences Limited’s return on equity (ROE) is 0.17 and return on invested capital (ROIC) is 15.68%.
Return on Equity (ROE)0.17
Return on Assets (ROA)0.14
Return on Invested Capital (ROIC)15.68%
Return on Capital Employed (ROCE)0.21
Revenue Per Employee10.36M
Profits Per Employee2.87M
Employee Count2,203
Asset Turnover0.70
Inventory Turnover2.39
Valuation Ratios
The current PE Ratio of Glenmark Life Sciences Limited is 18.7. Glenmark Life Sciences Limited’s PEG ratio is 0.00.
PE Ratio18.7
PS Ratio5.34
PB Ratio4.50
Price to Fair Value4.50
Price to FCF51.66
Price to Operating Cash Flow―
PEG Ratio0.00
Income Statement
In the last 12 months, Glenmark Life Sciences Limited had revenue of 22.83B and earned 4.71B in profits. Earnings per share was 38.43.
Revenue22.83B
Gross Profit12.43B
Operating Income8.98B
Pretax Income6.31B
Net Income4.71B
EBITDA6.86B
Earnings Per Share (EPS)38.43
Cash Flow
In the last 12 months, operating cash flow was 1.72B and capital expenditures -805.50M, giving a free cash flow of 913.92M billion.
Operating Cash Flow1.72B
Free Cash Flow913.92M
Free Cash Flow per Share7.45
Dividends & Yields
Glenmark Life Sciences Limited pays an annual dividend of ₹22.5, resulting in a dividend yield of 0.56%
Dividend Per Share₹22.5
Dividend Yield0.56%
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.76
52-Week Price Change-4.05%
50-Day Moving Average952.36
200-Day Moving Average942.70
Relative Strength Index (RSI)74.34
Average Volume (3m)7.13K
Important Dates
Glenmark Life Sciences Limited upcoming earnings date is Jul 31, 2026, Before Open (Confirmed).
Last Earnings DateApr 23, 2026
Next Earnings DateJul 31, 2026
Ex-Dividend Date―
Financial Position
Glenmark Life Sciences Limited as a current ratio of 4.97, with Debt / Equity ratio of ―
Current Ratio4.97
Quick Ratio3.53
Debt to Market Cap<0.01
Net Debt to EBITDA-0.02
Interest Coverage Ratio258.41
Taxes
In the past 12 months, Glenmark Life Sciences Limited has paid 1.60B in taxes.
Income Tax1.60B
Effective Tax Rate0.26
Enterprise Valuation
Glenmark Life Sciences Limited EV to EBITDA ratio is 17.64, with an EV/FCF ratio of 51.60.
EV to Sales5.33
EV to EBITDA17.64
EV to Free Cash Flow51.60
EV to Operating Cash Flow30.76
Balance Sheet
Glenmark Life Sciences Limited has ₹6.53B in cash and marketable securities with ₹1.13B in debt, giving a net cash position of ₹5.39B billion.
Cash & Marketable Securities₹6.53B
Total Debt₹1.13B
Net Cash₹5.39B
Net Cash Per Share₹43.95
Tangible Book Value Per Share₹228.29
Margins
Gross margin is ―, with operating margin of 26.30%, and net profit margin of 20.47%.
Gross Margin―
Operating Margin26.30%
Pretax Margin27.58%
Net Profit Margin20.47%
EBITDA Margin30.24%
EBIT Margin27.68%
Analyst Forecast
The average price target for Glenmark Life Sciences Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast10.48%
EPS Growth Forecast22.99%